Aptahem (APTA.SL) Stock Price

Aptahem Price

CLOSED
0.28
​
Market closed

Aptahem stock price

Access this data via the Eulerpool API

Aptahem business model & stock analysis

Aptahem AB is a biotechnology company, which engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. The company is headquartered in Malmo, Skane. The company went IPO on 2015-04-17. The firm was founded in 2014 and is located in Malmo, Sweden.

Frequently asked questions about Aptahem

Converted at the current exchange rate, the Aptahem share trades at 0.02 EUR (0.28 SEK).

The revenue cannot currently be calculated for Aptahem.

The profit cannot currently be calculated for Aptahem.

The P/E ratio cannot be calculated for Aptahem at the moment.

The P/S cannot be calculated for Aptahem currently.

The Eulerpool Quality Score for Aptahem is 2/10.

The ISIN of Aptahem is SE0022447173. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Aptahem is APTA.SL. The ticker symbol is used to trade Aptahem shares on the stock exchange.

Fair ValueTerminal
0.23 SEK
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website aptahem.com
Country
Sweden
Currency
SEK
Initial public offering
Apr 17, 2015
ISIN
SE0022447173
Cusip
W1R50S333
Market capitalization
9.07 M SEKMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.14
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-13.09 %
Last updated Oct 10, 2026, 2:43 AM

Aptahem Peer Group

All fundamentals and in-depth analysis of Aptahem

Our stock analysis for Aptahem stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aptahem. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.